TY - JOUR
T1 - The effectiveness of long-acting injectable antipsychotics versus oral antipsychotics in the maintenance treatment of outpatients with chronic schizophrenia
AU - Fang, Su Chen
AU - Liao, Ding Lieh
AU - Huang, Cheng Yi
AU - Hsu, Chun Chi
AU - Cheng, Shu Li
AU - Shao, Yu Hsuan J.
N1 - Funding Information:
We would like to thank the Bureau of Health Promotion, Department of Health of Taiwan, for the provision of the data. We are grateful to the Bali Psychiatric Center, Ministry of Health and Welfare, Taiwan (no. MOHW#10809), for funding this research. These sources had no further role in this study design, in the data collection and analysis, in the writing of the report, and in the decision to submit the paper for publication.
Publisher Copyright:
© 2020 John Wiley & Sons Ltd
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Objective: To compare the psychiatric service utilization between patients who only received long-acting injectable antipsychotics (LAIAs) and those who only received oral antipsychotics (OAPs) in the maintenance treatment of chronic schizophrenia. Methods: We constructed a cohort of chronic schizophrenia patients who underwent maintenance treatment from the Taiwan National Health Insurance Research Database in 2011 and followed these patients for 12 months. We included patients who had been diagnosed with schizophrenia for at least 3 years, were not hospitalized in 2011, and had received 1 year of maintenance treatment. Inverse probability of treatment weighting logistic, linear, and negative binomial regression models were used to estimate associated psychiatric services utilization and adjust for covariate imbalances between the LAIAs and OAPs groups. Results: Among 40,194 patients, 948 (2.36%) received only LAIAs and 39,246 (97.64%) received only OAPs. Compared with those who received only OAPs, the sole LAIAs users were associated with a lower percentage of psychiatric hospitalization (8.4% and 5.8%, respectively; odds ratio: 0.63, p <.01), shorter lengths of hospitalization days (82.8 and 65.9, respectively; coefficient [b]: −16.87, p =.03), and fewer emergency room visits (2.3 and 1.8, respectively; b: −0.24, p <.01) per patient. Conclusions: Chronic schizophrenia patients who received only LAIs had a lower risk of disease relapse and a reduction in psychiatric service utilization than those receiving only OAPs.
AB - Objective: To compare the psychiatric service utilization between patients who only received long-acting injectable antipsychotics (LAIAs) and those who only received oral antipsychotics (OAPs) in the maintenance treatment of chronic schizophrenia. Methods: We constructed a cohort of chronic schizophrenia patients who underwent maintenance treatment from the Taiwan National Health Insurance Research Database in 2011 and followed these patients for 12 months. We included patients who had been diagnosed with schizophrenia for at least 3 years, were not hospitalized in 2011, and had received 1 year of maintenance treatment. Inverse probability of treatment weighting logistic, linear, and negative binomial regression models were used to estimate associated psychiatric services utilization and adjust for covariate imbalances between the LAIAs and OAPs groups. Results: Among 40,194 patients, 948 (2.36%) received only LAIAs and 39,246 (97.64%) received only OAPs. Compared with those who received only OAPs, the sole LAIAs users were associated with a lower percentage of psychiatric hospitalization (8.4% and 5.8%, respectively; odds ratio: 0.63, p <.01), shorter lengths of hospitalization days (82.8 and 65.9, respectively; coefficient [b]: −16.87, p =.03), and fewer emergency room visits (2.3 and 1.8, respectively; b: −0.24, p <.01) per patient. Conclusions: Chronic schizophrenia patients who received only LAIs had a lower risk of disease relapse and a reduction in psychiatric service utilization than those receiving only OAPs.
KW - antipsychotics
KW - long-acting injectable antipsychotics
KW - maintenance treatment
KW - schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85081555818&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081555818&partnerID=8YFLogxK
U2 - 10.1002/hup.2729
DO - 10.1002/hup.2729
M3 - Article
AN - SCOPUS:85081555818
SN - 0885-6222
VL - 35
JO - Human Psychopharmacology
JF - Human Psychopharmacology
IS - 3
M1 - e2729
ER -